Get the Stockscreener App
0.389
2.38%
-0.0101
IGC Pharma Inc stock is traded at $0.389, with a volume of 582.55K.
It is down -2.38% in the last 24 hours and down -4.02% over the past month.
India Globalization Capital, Inc. engages in the development and commercialization of cannabis-based therapies to treat Alzheimer's, pain, nausea, eating disorders, several end points of Parkinson's, and epilepsy in humans, dogs, and cats. The company operates through two segments, Legacy Infrastructure and Medical Cannabis Based Alternative Therapies. The Legacy Infrastructure segment trades in infrastructure commodities, such as steel and iron ore; and rents heavy equipment. The Medical Cannabis Based Alternative Therapies segment offers IGC-501 for indications of neuropathic pain; Serosapse for indications of Parkinson's and other central nervous system disorders; Caesafin for seizures in cats and dogs; and Natrinol for indications of cancer and AIDS induced nausea and vomiting, as well as Hyalolex for Alzheimer's patients. The company was founded in 2005 and is based in Bethesda, Maryland.
See More
Previous Close:
$0.3991
Open:
$0.3885
24h Volume:
582.55K
Relative Volume:
0.54
Market Cap:
$35.77M
Revenue:
$1.22M
Net Income/Loss:
$-14.15M
P/E Ratio:
-1.4962
EPS:
-0.26
Net Cash Flow:
$-6.55M
1W Performance:
-3.80%
1M Performance:
-4.02%
6M Performance:
+39.39%
1Y Performance:
+6.71%
1-Day Range:
$0.38
$0.399
1-Week Range:
$0.38
$0.435
52-Week Range:
$0.2525
$0.4985
IGC Pharma Inc Stock (IGC) Company Profile
Name
IGC Pharma Inc
Sector
Industry
Phone
301-983-0998
Address
4336 Montgomery Avenue, Bethesda, MD
Compare IGC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.389 | 36.70M | 1.22M | -14.15M | -6.55M | -0.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.20 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
471.94 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
553.36 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
807.98 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.21 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
IGC Pharma Inc Stock (IGC) Latest News
Will IGC Pharma Inc. stock gain from government policiesMarket Growth Report & Risk Managed Trade Strategies - newser.com
Short interest data insights for IGC Pharma Inc.Market Risk Analysis & Accurate Entry and Exit Point Alerts - newser.com
What downside risks could hit IGC Pharma Inc. stockWeekly Trade Review & Fast Moving Stock Trade Plans - newser.com
Applying Wyckoff theory to IGC Pharma Inc. stockMarket Trend Report & Reliable Price Breakout Alerts - newser.com
Candlestick signals on IGC Pharma Inc. stock todayJuly 2025 News Drivers & High Accuracy Investment Signals - newser.com
IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders - Lelezard
600M authorized shares: IGC Pharma boosts authorization, grants 5,000,000 shares and elects two directors - Stock Titan
What to expect from IGC Pharma Inc. in the next 30 daysTrade Exit Summary & High Accuracy Trade Alerts - newser.com
Developing predictive dashboards with IGC Pharma Inc. dataJuly 2025 PostEarnings & Weekly Watchlist for Hot Stocks - newser.com
Will IGC Pharma Inc. stock profit from AI boom2025 Market Trends & Technical Buy Zone Confirmation - newser.com
IGC Pharma Subsidiary Signs Asset Sale Agreement - MSN
What candlestick patterns are forming on IGC Pharma Inc.Portfolio Update Report & Risk Adjusted Swing Trade Ideas - newser.com
How IGC Pharma Inc. stock reacts to monetary easingJuly 2025 Recap & AI Based Trade Execution Alerts - newser.com
IGC's Latest Discovery in Alzheimer's Treatment Shows Promise - GuruFocus
IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease - ACCESS Newswire
Kd 3.95 μM: IGC Pharma's IGC-1C Modulates Tau LLPS, Inhibits and Dissolves Condensates - Stock Titan
Will IGC Pharma Inc. (IGS1) stock rise with strong economy2025 Price Momentum & Fast Exit Strategy with Risk Control - newser.com
IGC Pharma, Inc. (NYSEAMERICAN:IGC) Sees Significant Decline in Short Interest - Defense World
Is IGC Pharma Inc. (IGS1) stock inflation resilient2025 Fundamental Recap & Consistent Profit Alerts - newser.com
Real time scanner hits for IGC Pharma Inc. explained2025 Market Overview & Weekly High Potential Stock Alerts - newser.com
Is IGC Pharma Inc. stock a buy in volatile marketsLong Setup & Weekly Top Gainers Alerts - newser.com
How IGC Pharma Inc. stock benefits from global expansionEarnings Summary Report & Weekly Market Pulse Updates - newser.com
Is IGC Pharma Inc. stock a contrarian buy2025 Investor Takeaways & Free Fast Entry Momentum Trade Alerts - newser.com
Can IGC Pharma Inc. hit a new high this monthMarket Rally & Weekly Market Pulse Updates - newser.com
How institutional ownership impacts IGC Pharma Inc. stockMarket Trend Review & Verified Technical Signals - newser.com
Institutional scanner results for IGC Pharma Inc.2025 Market Sentiment & Smart Investment Allocation Tips - newser.com
Can IGC Pharma Inc. stock attract ESG capital inflowsJuly 2025 Volume & Fast Gain Swing Trade Alerts - newser.com
What analysts say about IGC Pharma Inc IGS1 stockMid Cap Growth Trends & Low Risk Portfolio Growth - earlytimes.in
IGC Pharma subsidiary agrees to asset sale valued at $2.7 million - Investing.com Nigeria
IGC Pharma Inc Stock (IGC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):